05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£14,068,263 |
Nicolas Loebel |
3,538,991 |
£318,509 |
Junaid Bajwa |
1,193,697 |
£107,433 |
Jean Duvall |
1,163,529 |
£104,718 |
Jean Charest |
353,356 |
£31,802 |
Simon Sinclair |
256,327 |
£23,069 |
Carolyn Cross |
118,091,377 |
£10,628,224 |
M&G Plc |
40,588,235 |
£3,652,941 |
Robert Cross |
25,858,400 |
£2,327,256 |
Albemarle Life Sciences Fund |
15,105,882 |
£1,359,529 |
CRUX Asset Management |
9,298,090 |
£836,828 |
Chelverton Asset Management |
7,957,311 |
£716,158 |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research